Xin Lang Cai Jing·2026-01-22 03:32Group 1 - The law firm Shanghai Jiucheng is representing investors in lawsuits against Xilong Science and Puli Pharmaceutical for false statements leading to financial losses [1][2] - Xilong Science was found to have inflated its revenue by approximately 597.65 million yuan in 2020, 1.46 billion yuan in 2021, and 785.35 million yuan in the first half of 2022, affecting its reported profits significantly [1] - Puli Pharmaceutical reported inflated revenues of about 514.60 million yuan in 2021 and 515.90 million yuan in 2022, with corresponding profit overstatements of 308.02 million yuan and 387.42 million yuan, respectively [2] Group 2 - Investors who purchased Puli Pharmaceutical shares between April 26, 2022, and April 17, 2024, or Xilong Science shares between April 29, 2021, and April 29, 2023, may still initiate claims for compensation [3] - The law firm has a history of successfully representing investors in similar cases, having handled nearly 200 cases resulting in victories or settlements [3]